Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose for COVID 19.- AstraZeneca
Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “Vaxzevria is effective against all severities of COVID-19 and it plays a critical role in combatting the pandemic. Unless TTS was identified after the first dose, these results support the administration of the two-dose schedule of Vaxzevria, as indicated, to help provide protection against COVID-19 including against rising variants of concern.”
The analysis was conducted using AstraZeneca’s global safety database, which captures all spontaneously reported adverse events from real-world use of its medicines and vaccines worldwide. Reported cases of TTS globally were included up to the cut-off date of April 30 occurring within 14 days of administration of the first or second dose of Vaxzevria. The results are in line with recent reports in the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Report, the UK system for collecting and monitoring information on safety concerns, which also show low rates of TTS after a second dose.
No specific risk factors or definitive cause for TTS following COVID-19 vaccination have been identified and AstraZeneca continues to perform and support ongoing investigations of potential mechanisms. Furthermore, these very rare events can be avoided when symptoms are identified and treated appropriately.
See-
"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis"-Prakash Bhuyan, Jennie Medin, Hugo Gomes da Silva, et al. Published: July 27, 2021DOI:https://doi.org/10.1016/S0140-6736(21)01693-7.The Lancet.